Last reviewed · How we verify
CRB-601 monoclonal antibody — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CRB-601 monoclonal antibody (CRB-601 monoclonal antibody) — Corbus Pharmaceuticals Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CRB-601 monoclonal antibody TARGET | CRB-601 monoclonal antibody | Corbus Pharmaceuticals Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CRB-601 monoclonal antibody CI watch — RSS
- CRB-601 monoclonal antibody CI watch — Atom
- CRB-601 monoclonal antibody CI watch — JSON
- CRB-601 monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). CRB-601 monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/crb-601-monoclonal-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab